Spondyloarthritis & psoriatic arthritis
Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARdiovascular in ReuMAtology (CARMA) Project cohort after 7.5 years of follow-up
Authors' conclusion
In patients from the Spanish CARMA project, the four algorithms tested accurately discriminated those AS patients with higher CV risk and those with lower CV risk. Moreover, a model that includes QRISK3 and SCORE2 combined the best discrimination ability of QRISK3 with the best calibration of SCORE2.
Study context
- Population
- Spanish patients with ankylosing spondylitis (AS) without prior cardiovascular (CV) events, CARMA project, rheumatology outpatient clinics of tertiary centres, followed 7.5 years4,907 years of follow-up
- Participants
- 684 patients
- Exposure
- QRISK3 vs SCORE, modified SCORE (mSCORE) EULAR 2015/2016, SCORE2, and QRISK3 combined with each
- Outcome
- Predictive value of CV risk algorithms for CV events and CV mortality
- Follow-up
- 7.5 years
Methodological detailsretrospective testing of risk algorithms on baseline data, tertiary centres
- Retrospective testing of risk algorithms on baseline data
- Tertiary centres
Main finding
As reported in the abstract
| Group | AIC | BIC |
|---|---|---|
| QRISK3 + SCORE2 | 406.70 | 415.66 |
QRISK3 + SCORE2
AIC406.70
BIC415.66
Observational data: associations, not effects.
Further findings
CV events, linearized rate · 7.5 years
- AS patients with CV events
- 33
- Linearized rate per 1000 person-years
- 6.73 (95 % CI: 4.63, 9.44)
Original publication
Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up. Semin Arthritis Rheum. Published 27 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →